Anglia Ruskin Research Online (ARRO)
Browse
Allen_2019_3.pdf (363.73 kB)

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol

Download (363.73 kB)
journal contribution
posted on 2023-08-30, 16:42 authored by Augusto Azuara-Blanco, Nicola Logan, Niall Strang, Kathryn Saunders, Peter M. Allen, Ruth Weir, Paul Doherty, Catherine Adams, Evie Gardner, Ruth Hogg, Margaret McFarland, Jennifer Preston, Rejina Verghis, James J. Loughman, Ian Flitcroft, David A. Mackey, Samantha Sze-Yee Lee, Christopher Hammond, Nathan G. Congdon, Mike Clarke
Background/aims: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6–12 years with myopia of −0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population.

History

Refereed

  • Yes

Volume

104

Issue number

7

Page range

950-955

Publication title

British Journal of Ophthalmology

ISSN

1468-2079

Publisher

BMJ

File version

  • Accepted version

Language

  • eng

Legacy posted date

2019-11-01

Legacy creation date

2019-11-01

Legacy Faculty/School/Department

Faculty of Science & Engineering

Usage metrics

    ARU Outputs

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC